紫杉醇与肿瘤免疫的研究进展

被引：31

作者：

罗光华 ^{[1
,2
]}

郭莉莉 ^{[2
]}

刘丽华 ^{[1
]}

机构：

[1] 河北医科大学第四医院临床生物治疗科

[2] 邯钢医院肿瘤内科

来源：

中国肿瘤生物治疗杂志 | 2013年 / 20卷 / 02期

关键词：

紫杉醇; 免疫细胞; 肿瘤; 过继细胞免疫治疗;

D O I：

暂无

中图分类号：

R730.5 [肿瘤治疗学];

学科分类号：

100214 [肿瘤学];

摘要：

紫杉醇(paclitaxel,PTX)是一种有丝分裂抑制剂,通过促进微管蛋白聚合、抑制解聚、保持微管蛋白稳定、抑制细胞有丝分裂和促进肿瘤细胞凋亡发挥抗肿瘤作用。通过研究紫杉醇的结构和功能,发现紫杉醇对免疫细胞包括效应性T细胞、树突状细胞(dendritic cell,DC)、自然杀伤细胞(Natural cell,NK)、调节性T细胞(regulatory T cell,Treg)和巨噬细胞(mac-rophage)等具有广泛调节作用,紫杉醇杀伤肿瘤细胞的同时逆转肿瘤的免疫逃逸。紫杉醇与过继细胞免疫治疗联合可减轻化疗的不良反应、增加化疗效果。紫杉醇在非小细胞肺癌化疗中抑制调节性T细胞的数量和功能,在乳腺癌化疗过程中增强NK细胞抗肿瘤活性,在卵巢癌化疗中增加肿瘤抗原的免疫原性及促进DC的抗原提呈作用。总之,紫杉醇的免疫调节功能在抗肿瘤领域有广泛的应用前景。

引用

收藏

页码：251 / 254

页数：4

相关论文

共 13 条

[1]

Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: More than one plus one? [J].

Thanendrarajan, Sharmilan ;

Nowak, Michael ;

Abken, Hinrich ;

Schmidt-Wolf, Ingo G. H. .

LEUKEMIA RESEARCH, 2011, 35 (09) :1136-1142

[2]

Immunity, Inflammation, and Cancer [J].

Grivennikov, Sergei I. ;

Greten, Florian R. ;

Karin, Michael .

CELL, 2010, 140 (06) :883-899

[3]

Tumor-Infiltrating Foxp3+Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small Cell Lung Cancer [J].

Shimizu, Katsuhiko ;

Nakata, Masao ;

Hirami, Yuji ;

Yukawa, Takuro ;

Maeda, Ai ;

Tanemoto, Kazuo .

JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) :585-590

[4]

Somatic Single Hits Inactivate the X-Linked Tumor Suppressor FOXP3 in the Prostate [J].

Wang, Lizhong ;

Liu, Runhua ;

Li, Weiquan ;

Chen, Chong ;

Katoh, Hiroto ;

Chen, Guo-Yun ;

McNally, Beth ;

Lin, Lin ;

Zhou, Penghui ;

Zuo, Tao ;

Cooney, Kathleen A. ;

Liu, Yang ;

Zheng, Pan .

CANCER CELL, 2009, 16 (04) :336-346

[5]

CD8+CD28-cells and CD4+CD25+regulatory T cells in the peripheral blood of advanced stage lung cancer patients [J].

Karagoz, Bulent ;

Bilgi, Oguz ;

Gumus, Mahmut ;

Erikci, Alev Akyol ;

Sayan, Ozkan ;

Turken, Orhan ;

Kandemir, Emin Goekhan ;

Ozturk, Ahmet ;

Yaylaci, Mustafa .

MEDICAL ONCOLOGY, 2010, 27 (01) :29-33

[6]

Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse [J].

Vicari, Alain P. ;

Luu, Rachel ;

Zhang, Ningli ;

Patel, Shobhna ;

Makinen, Shawn R. ;

Hanson, Douglas C. ;

Weeratna, Risini D. ;

Krieg, Arthur M. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (04) :615-628

[7]

Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy [J].

Zhang, Lei ;

Dermawan, Kamtai ;

Jin, Meilin ;

Liu, Rongjun ;

Zheng, Huiru ;

Xu, Lin ;

Zhang, Yi ;

Cai, Yuchan ;

Chu, Yiwei ;

Xiong, Sidong .

CLINICAL IMMUNOLOGY, 2008, 129 (02) :219-229

[8]

Post-chemotherapeutic administration of interleukin-12 retards tumor growth and enhances immune cell function: Combination therapy using paclitaxel and IL-12 [J].

Pressley, Jennifer S. ;

Elgert, Klaus D. .

CANCER INVESTIGATION, 2006, 24 (04) :351-359

[9]

Enhancement of antitumor effects of paclitaxel (taxol) in combination with red ginseng acidic polysaccharide (RGAP) [J].

Shin, HJ ;

Kim, YS ;

Kwak, YS ;

Song, YB ;

Kim, YS ;

Park, JD .

PLANTA MEDICA, 2004, 70 (11) :1033-1038

[10]

Paclitaxel probably enhances cytotoxicity of natural killer cells against breast carcinoma cells by increasing perforin production [J].

Kubo, M ;

Morisaki, T ;

Matsumoto, K ;

Tasaki, A ;

Yamanaka, N ;

Nakashima, H ;

Kuroki, H ;

Nakamura, K ;

Nakamura, M ;

Katano, M .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (05) :468-476